Haematology analyzers provide complete blood count (CBC) with a three-part differential white blood cell (WBC) count and can detect small cell populations to diagnose rare blood conditions, measure cell morphology. The main products in haematology analyzers and reagents are haematology analyzers, hemostasis analyzers, plasma protein analyzers, haemoglobin analyzers, erythrocyte sedimentation rate analyzers, coagulation analyser, flow cytometers, slide stainers, differential counters, and haematology stains. The hematology analysers are devices that measure the concentration of haemoglobin in a blood sample. The various applications include anemias, blood cancers, hemorrhagic conditions, infection-related conditions, immune system-related conditions, and others that are used by end-users such as specialised research institutes, hospitals, specialised diagnostic centres, and others. The haematology analyzers and reagents market research report is one of a series of new reports from The Business Research Company that provides haematology analyzers and reagents market statistics, including haematology analyzers and reagents industry global market size, regional shares, competitors with a haematology analyzers and reagents market share, detailed haematology analyzers and reagents market segments, market trends and opportunities, and any further data you may need to thrive in the haematology analyzers and reagents industry. This haematology analyzers and reagents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hematology analyzers and reagents market grew from $4.14 billion in 2022 to $4.56 billion in 2023 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hematology analyzers and reagents market is expected to grow from $5.67 billion in 2027 at a CAGR of 5.6%. The rising number of blood donations globally is driving the hematology analyzers and reagents market as hematology analyzers are used to test and screen blood in blood banks. Blood collected from donors through blood donation camps or bloodmobiles is sent to blood banks where hematology analyzers are used to screen and test the blood. These screening tests determine the blood type, analyze the blood plasma and detect infectious diseases. Blood banks are witnessing a huge outflow of blood to hospitals and other end-users and an inflow of blood from blood donations daily. According to the WHO, there was an increase of 7.8 million blood donations from voluntary unpaid donors. As the number of people donating blood increases, the demand for hematology analyzers and reagents increases, thereby driving the market growth. Recalls of defective hematology analyzers are acting as a restraint on the hematology analyzers and reagents market. A product recall is done by the manufacturer or developer of the product as a precautionary measure when safety issues or defects are discovered that can endanger the consumer. A faulty hematology analyzer may provide wrong results and may lead to misdiagnosis, affecting consumer confidence in the analyzers. Regulatory authorities caution healthcare professionals to be aware of the potential for inaccurate diagnostic results with these analyzers and to take appropriate actions including the use of alternative diagnostic testing or confirming analyzer results with manual scanning or estimate of cell counts. For instance, Beckman Coulter Life Sciences recalled its DxH800 and DxH600, and DxH 900 hematology analyzers due to the risk of inaccurate results. Such kind product recalls not only pose a serious safety risk to the public but can also cause significant financial and reputational damage to the companies concerned. Hematology analyzers manufacturers are increasingly investing in the research and development of analyzers with microfluidics technology that use low volumes of samples and reagents. Microfluidics deal with the flow of liquids inside channels as small as a few micrometers. Low reagent consumption by hematology analyzers with microfluidics technology helps reduce operating costs significantly. For instance, the HA5 hematology system from BioSystems is based on microfluidics technology and uses approximately 75% fewer reagents compared to normal hematology analyzers. Also, the respons®3H and respons®5H hematology systems by DiaSys use microfluidics technology and consume 70% fewer reagents. In May 2021, Soulbrain, a South Korean chemicals company, acquired PixCell Medical for an undisclosed amount. The acquisition would support Soulbrain’s growth strategy in the fields of diagnostics and point-of-care testing. PixCell is an Israeli maker of blood test analyzers. Major players in the haematology analyzers market are Abbott, Bio-Rad Laboratories, Horiba, Siemens, Sysmex, BioSystems, Boule, Danaher, Diatron, and Drew Scientific. North America was the largest region in the haematology analyzers market in 2022. Western Europe was the second largest region in the global haematology analyzers market report. The regions covered in the global haematology analyzers and reagents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the haematology analyzers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The haematology analyzers market consists of sales electrolyte analyzer, hemocoagulometer, enzyme standard instrument, blood gas analyzer and immunoturbidimeter. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global haematology analyzers and reagents market is segmented - 1) By Product: Hematology Analysers, Hemostasis Analysers, Plasma Protein Analysers, Hemoglobin Analysers, Erythrocyte Sedimentation Rate Analyser, Coagulation Analyser, Flow Cytometers, Slide Stainers, Differential Counters, Hematology Stains 2) By Applications: Anemias, Blood Cancers, Hemorrhagic Conditions, Infection Related Conditions, Immune System Related Conditions, Other Applications 3) By End User: Specialized Research Institutes, Hospitals, Specialized Diagnostic Centers, Other End Users

Hematology diagnostic devices and equipment are used to diagnose diseases related to blood, vascular systems, bone marrow, autoimmune disorders, and hemostasis. The main products of the hematology diagnostics devices and equipment are instruments and consumables. Hematology diagnostic instruments are used to diagnose diseases related to blood, vascular systems, bone marrow, autoimmune disorders, and hemostasis. The hematology diagnostics consumables involved are reagents, stains, and others, and the hematology diagnostics instruments involved are analyzers, flow cytometers, and others. These are used in various applications, including drug testing, autoimmune disease, cancer, diabetes mellitus, infectious disease, and others. The end-users are hospitals, specialized diagnostic centres, and specialized research institutes. The hematology diagnostics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides hematology diagnostics devices and equipment market statistics, including hematology diagnostics devices and equipment industry global market size, regional shares, competitors with a hematology diagnostics devices and equipment market share, detailed hematology diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the hematology diagnostics devices and equipment industry. This hematology diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hematology diagnostic devices and equipment market size will grow from $1.89 billion in 2022 to $2.12 billion in 2023 at a compound annual growth rate (CAGR) of 12.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hematology diagnostic devices and equipment market size is expected to grow to $3.04 billion in 2027 at a CAGR of 9.4%. Hematology diagnostic devices are driven by the increase in the prevalence of blood disorders. Hematology diagnostic devices are widely used to identify the type of blood disorder. A blood disorder is a condition which is impacting the count of the blood cells like red blood cells, white blood cells, platelets, etc. Blood disorders affect millions of people each year across the world irrespective of age, race, and sex. E.g. As per the World Health Organization, Hemoglobin disorder is affecting 75% of the total births globally and the prevalence of Anemia is 12.7% in men. Product recall is one of the major problems that companies are facing. Product recalls are the process of returning faulty devices which can be due to errors in the manufacturing of the device. Because of the faulty devices tests conducted in the diagnostic centres may get affected. For example, Becton Dickinson (BD) and Company recalled Vacutainer EDTA Blood Collection Tubes because they are affecting the test due to the chemical interference of test tubes with the blood samples. This recall was classified as Class I recall, the most serious type of recall, by the Food and Drug Administration (FDA). Such product recalls can negatively affect market growth. Companies in the field of hematology diagnostic devices are increasingly investing in automation technology. Automation technology advancements are driving the demand for hematology analyzers, and this automation will reduce the errors caused by the manual practices in the diagnostic centres. For example, top companies like Sysmex acquired a CLIA waiver for a new automated hematology analyzer, and by selling this product, Sysmex makes it possible for clinical facilities to perform hematology testing without any manual errors. CLIA regulations establish quality standards for laboratory testing performed on specimens from humans, such as blood, body fluid, and tissue, for diagnosis, prevention, or treatment of disease, or assessment of health. The hematology diagnostic devices market has a potential market to grow rapidly but stringent regulatory policies are restricting their growth. The FDA currently regulates class I, class II, and class III hematology devices. This means that class I hemostasis devices are regulated to use these devices are exempt from the premarket notification requirements and they only be used for the general controls. Regulations for class II devices are exempt from the premarket notification requirements and they can be used for special controls. Class III is the most stringent category as it requires premarket approval (PMA). Major players in the hematology diagnostics devices and equipment market are Abbott Diagnostics, Beckman Coulter, Bio-Rad Laboratories, Drucker Diagnostics, Horiba Ltd., Instrumentation Laboratory Inc., Siemens Healthcare, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., F. Hoffmann-La Roche AG, and Thermo Fisher Scientific Inc. North America was the largest region in the global hematology diagnostics devices and equipment market in 2022. Asia-Pacific was the second-largest region in the hematology diagnostics devices and equipment market. The regions covered in global hematology diagnostics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the hematology diagnostic devices are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The hematology diagnostic devices and equipment market consists of sales of flow cytometers, slide strainers, automated cell counters, red cell indices devices, micro sedimentation centrifuges, or blood volume measuring devices, occult blood tests, platelet aggregometer, erythrocyte sedimentation rate tests, red blood cell enzyme assay kits, glutathione reductase assays, and hematology reagents that are used for the diagnosis of hematology. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global hematology diagnostic devices and equipment market is segmented - 1) By Product: Instruments, Consumables 2) By End User: Hospitals, Specialized Diagnostic Centers, Specialized Research Institutes 3) By Instruments: Analyzers, Flow cytometers, Other Instruments 4) By Consumables: Reagents, Stains, Other Consumables 5) By Application: Drug Testing, Auto Immune Disease, Cancer, Diabetes Mellitus, Infectious Disease, Other Applications

Hemostasis is the process of slowing and stopping the blood flow to initiate wound healing after a vascular injury. With the help of hemostasis diagnostic devices, the cause of bleeding during surgery can be predicted by identifying any hemostatic defects in patients. The main products of hemostasis diagnostic devices and equipment are analyzers, coagulation instruments, other hemostasis instruments, and reagents and kits. A hemostasis diagnostic analyzer is a tool utilised to predict the cause of bleeding during surgery by identifying any hemostatic defects. The hemostasis diagnostic devices and equipment are automated, semi-automated, and manual and are used by hospitals, clinics, independent diagnostic, laboratories, and others. The hemostasis diagnostic devices and equipment market research report is one of a series of new reports from The Business Research Company that provides hemostasis diagnostic devices and equipment market statistics, including hemostasis diagnostic devices and equipment industry global market size, regional shares, competitors with a hemostasis diagnostic devices and equipment market share, detailed hemostasis diagnostic devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the hemostasis diagnostic devices and equipment industry. This hemostasis diagnostic devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hemostasis diagnostic devices and equipment market size will grow from $4.77 billion in 2022 to $5.4 billion in 2023 at a compound annual growth rate (CAGR) of 13.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hemostasis diagnostic devices and equipment market size is expected to grow to $8 billion in 2027 at a CAGR of 10.3%. The increased likelihood of older people being diagnosed with a disease is driving the number of surgeries such as cardiovascular diseases (CVD), using hemostasis devices. Due to the higher incidence of diseases with advancing age, there is an increase in the number of surgeries in elderly patients nowadays. These hemostasis devices are very efficient in speeding up the natural process of clotting in the blood and can monitor anticoagulation and transfusion therapy guidance in any surgery. According to the American Heart Association report, Americans older than 80 have a high risk of devolving a cardiovascular disease (CVD), around 83% of men and 87.1% of females will be suffering from any form of CVD, therefore, to improve the comfort of the patient and the success rate of surgeries as a result hemostasis device has been implemented widely. The use of hemostasis devices in hospitals or clinics requires a very lengthy approval procedure which is restraining the market. Before hemostasis devices can enter the market for commercial use they have to clear the regulations set by the Code of Federal Regulations (title 21). The process of approval consists firstly identification of the device, secondly classification of the device and finally, the date of the pre-market approval (PMA) or the notice of completion of prescription drug plan (PDP) is required. It is a very long and time-consuming approval process that discourages new entrants from entering this market. For example, Cardiva medical Inc. had to wait for a processing period of four months before they received approval to change the existing equipment with a newer and modern one. The emergence of new and improved technology in the hemostasis diagnostic device and equipment market. To improve the quality and success rate of operations, new and improved technology such as the collagen vascular hemostasis devices have been implemented. Collagen is the main structural protein found in skin and other connective tissues. It is widely used in purified form for cosmetic surgical treatments and has now emerged in the hemostasis diagnostic devices market. A patient can face immobility right after a femoral surgery leading to increased discomfort, as a result, collagen-based closure devices have been implemented. According to a study conducted by the American Journal of Neuroradiology which they surveyed 698 Angio-Seal closures, using the Angio seal reduced the average time before mobilization by close to 15 minutes with no major complications. Angio seal is a type of collagen hemostasis device which reduces the average time of hemostasis and betters the mobilization of the patient. In 2021, Baxter International Inc., a leading global medical products company, has announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc for up to $60.8 million, as well as $25 million paid upfront. This acquisition helps the transaction reinforces Baxter’s strategy of acquiring products and technologies that both complement and augment the company’s leading portfolio. CryoLife, Inc. is one of the world's leading contemporary medical device companies. Major players in the hemostasis diagnostic devices and equipment market are C.R. Bard, Baxter International Inc., Pfizer Inc., Johnson & Johnson, Abbott Laboratories, Beckman Coulter Inc., Becton, Dickinson and Company, Chrono-Log Corporation, CSL Behring LLC, and F. Hoffmann-La Roche Ltd. North America was the largest region in the global hemostasis diagnostic devices and equipment market in 2022. Asia-Pacific was the second-largest region in the hemostasis diagnostic devices and equipment market. The regions covered in the global hemostasis diagnostic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the hemostasis diagnostic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. Hemostasis diagnostic devices and equipment consists of sales of instruments such as analyzers, coagulation instruments, other hemostasis instruments, and reagents and kits that are used in hemostasis diagnostics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global hemostasis diagnostic devices and equipment market is segmented - 1) By Product: Analyzers, Coagulation Instrument, Other Hemostasis Instruments, Reagents and Kits 2) By End User: Hospitals, Clinics, Independent Diagnostic, Laboratories, Other End Users 3) By Device Technology: Automated, Semi-Automated, Manual

Alpha mannosidosis refers to a rare genetic disorder defined by the body's cells' inability to adequately break down specific groups of complex sugars. Numerous bodily organs and systems, including the central nervous system, are impacted by sugar buildup. The disease's effects might vary greatly from person to person. The main types of therapy for alpha mannosidosis are bone marrow transplant (BMT), enzyme replacement therapy (ERT), peripheral blood stem cell transplantation (PBSCT) and gene therapy. A bone marrow transplant is a procedure in which dysfunctional marrow is replaced with healthy marrow. Enzyme replacement therapy includes replacing a defective enzyme in people who are lacking or deficient in that enzyme. Peripheral blood stem cell transplantation is a procedure in which the patient whose stem cells have been destroyed by disease or by radiation or high doses of anticancer drugs, receives healthy stem cells. Gene therapy is a procedure in which DNA is introduced to a patient to treat a genetic disease. The different types of indications include Type I, Type II and Type III and are implemented in a wide range of verticals such as hospitals and speciality clinics. The alpha mannosidosis market research report is one of a series of new reports from The Business Research Company that provides alpha mannosidosis market statistics, including alpha mannosidosis industry global market size, regional shares, competitors with a alpha mannosidosis market share, detailed alpha mannosidosis market segments, market trends and opportunities, and any further data you may need to thrive in the alpha mannosidosis industry. This alpha mannosidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global alpha mannosidosis market size grew from $10.59 billion in 2022 to $12.65 billion in 2023 at a compound annual growth rate (CAGR) of 19.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The alpha mannosidosis market size is expected to grow to $24.27 billion in 2027 at a CAGR of 17.7%. The increasing investments in research are expected to contribute to the growth of the alpha mannosidosis market in the forecast period. Currently, in the alpha mannosidosis market, only one company has therapies for rare genetic diseases. However, several firms have products in the clinical stages, which will boost market demand in the forecast period. For instance, in 2020, the EU clinical trials database lists 39,219 clinical trials with a EudraCT protocol, 6,426 of which are clinical trials involving subjects under the age of 18. Therefore, the increasing investments in research fuel the growth of the alpha mannosidosis market. The advancements in treatment for alpha mannosidosis like pharmacological therapy are gaining traction in the alpha mannosidosis market. For instance, in 2018 – Chiesi Group, an international research-focused Healthcare company, announced that it has received a positive opinion recommending the marketing authorization of Velmanase Alfa, under the brand name Lamzede from the European Medicines Agency Committee for Medicinal Products for Human Use. Lamzede is an enzyme replacement therapy intended to provide or supplement natural alpha-mannosidase, an enzyme that helps with the degradation of mannose–rich oligosaccharides and thus prevents their accumulation in various tissues in the body. Major players in the alpha mannosidosis market are Chiesi Farmaceutici S.p.A., Nuo Therapeutics, and Zymenex. North America was the largest region in the alpha mannosidosis market in 2022. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the alpha mannosidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The alpha mannosidosis market includes revenues earned by entities by intellectual disability, skeletal abnormalities, hearing loss, and muscle weakness. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.  The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global alpha mannosidosis market is segmented - 1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Peripheral Blood Stem Cell Transplantation (PBSCT), Gene Therapy 2) By Indication: Type I, Type II, Type III 3) By End-User: Hospitals, Speciality Clinics

Apheresis consumables and equipment are devices through which the blood drawn from a donor is separated into its components through plasma exchange, stem cell harvest, photopheresis, and low-density lipid removal techniques. Further, the required components like plasma or platelets are retained and the remaining is passed to the circulation. The main products of apheresis consumables and equipment are disposables and devices. The apheresis consumables are the products that are used in apheresis technology. The technologies involved in disposables and devices are centrifugation and membrane filtration and procedures involved are photopheresis, plasmapheresis, LDL apheresis, plateletpheresis, leukapheresis, erythrocytapheresis, and others. The apheresis consumables and equipment are used in applications such as renal disease, neurology, haematology, and others. The apheresis consumables and equipment market research report is one of a series of new reports from The Business Research Company that provides apheresis consumables and equipment market statistics, including apheresis consumables and equipment industry global market size, regional shares, competitors with a apheresis consumables and equipment market share, detailed apheresis consumables and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the apheresis consumables and equipment industry. This apheresis consumables and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global apheresis consumables and equipment market grew from $2.65 billion in 2022 to $2.96 billion in 2023 at a compound annual growth rate (CAGR) of 11.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The apheresis consumables and equipment market is expected to grow from $4.6 billion in 2027 at a CAGR of 11.6%. The cases of blood disorders are on the rise globally, creating a need for blood transfusions. Apheresis Equipment helps to transfuse blood for blood disorders like sickle cell anemia, leukemia, and cancer. According to a report published by Leukemia and Lymphoma Society, 60,300 people in the USA are expected to be diagnosed with leukemia, and one person is diagnosed with blood cancer every 3 minutes requiring an immediate blood transfusion. According to the American Society of Hematology, 100,000 Americans possessed sickle cell Anemia and another 2 million people carry the trait requiring Apheresis Equipment for blood transfusion. According to the International Agency for Research on Cancer (IARC), by 2040, 16.3 million new cancer cases are expected to be reported worldwide. Cancer treatment requires at least 8 units of blood per patient per procedure, thus requiring blood component collection and blood transfusion. Thus, such a high prevalence of these blood disorders increases demand for apheresis consumables and equipment. Lack of awareness about apheresis consumables and equipment restrains the apheresis consumables and equipment market. Patients in developing countries like Africa. and the Middle East are unaware of apheresis consumables and equipment and how the device can be advantageous to treating blood disorders and few lack access to the device at the medical facility due to high cost or unavailability. According to the journal of clinical apheresis, only Nigeria in the whole of West Africa. uses apheresis equipment to collect platelets. Most countries are unaware of the use of apheresis, leading to low demand for apheresis consumables and equipment, and hindering the growth of the market. Companies are developing technologically advanced and automated products that enhance the efficiency of the product (blood). Technologically advanced products like automatic apheresis equipment with continuous flow centrifugation, automated interface system, and customized anticoagulant infusion system are being developed and adopted. The adoption of automated Apheresis equipment has resulted in a more efficient and rapid blood separation process. For instance, Companies like Haemonetics Corp have developed automated apheresis equipment NexSys PCS that increases productivity and improves quality and compliance in plasma collection centres. Major players in the apheresis consumables and equipment market are Asahi Kasei Medical, Haemonetics Corporation, Kawasumi Laboratories Inc., Fresenius SE & Co. KGaA, Terumo BCT, FenwalInc., Braun Melsungen AG, TherakosInc., HemaCare Corporation, and Cerus Corporation. North America was the largest region in the apheresis consumables and equipment market in 2022. Western Europe was the second largest region in the global apheresis consumables and equipment market report. The regions covered in global apheresis consumables and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the apheresis consumables and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The apheresis consumables and equipment market consist of sales of equipment and consumables. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global apheresis consumables and equipment market is segmented - 1) By Product: Disposables, Devices 2) By Technology: Centrifugation, Membrane Filtration 3) By Application: Renal Disease, Neurology, Hematology, Other Applications 4) By Procedure: Photopheresis, Plasmapheresis, LDL Apheresis, Plateletpheresis, Leukapheresis, Erythrocytapheresis, Other Procedures

Inflammatory bowel disease treatment refers to anti-inflammatory medications that are commonly used to treat mild to moderate ulcerative colitis. Aminosalicylates such as mesalamine (Delzicol, Rowasa, and other brands), balsalazide (Colazal), and olsalazine are anti-inflammatories (Dipentum). The main drug class of inflammatory bowel disease treatment include aminosalicylates, corticosteroids, TNF inhibitors, IL inhibitors, anti-integrin, JAK inhibitors, and others. Aminosalicylates refer to a class of medications used to treat and prevent ulcerative colitis flare-ups and Crohn's disease. The functioning of aminosalicylates is based on inhibiting the production of cyclo-oxygenase and prostaglandin, thromboxane synthetase, platelet-activating factor synthetase, and interleukin-1 by macrophages. Both orally and injectable administered inflammatory bowel disease treatment are used in the treatment of Crohn’s disease and ulcerative colitis. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The inflammatory bowel disease treatment market research report is one of a series of new reports from The Business Research Company that provides inflammatory bowel disease treatment market statistics, including inflammatory bowel disease treatment industry global market size, regional shares, competitors with an inflammatory bowel disease treatment market share, detailed inflammatory bowel disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the inflammatory bowel disease treatment industry. This inflammatory bowel disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global inflammatory bowel disease treatment market size grew from $20.39 billion in 2022 to $21.3 billion in 2023 at a compound annual growth rate (CAGR) of 4.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The inflammatory bowel disease treatment market size is expected to grow to $25.74 billion in 2027 at a CAGR of 4.8%. The rising prevalence of Crohn’s disease and ulcerative colitis is significantly driving the inflammatory bowel disease treatment market. Crohn’s disease and ulcerative colitis are types of inflammatory bowel diseases (IBD) that cause inflammation and ulcers (sores) in the digestive tracts. The rising cases of Crohn’s disease and ulcerative colitis are expected to boost demand for inflammatory bowel disease treatments, as they are widely used to reduce bowel inflammation and reduce and prevent medical complications. For instance, according to March 2022 research published in the United States National Library of Medicine, a US-based medical library, around 1.6 million Americans currently suffer from inflammatory bowel disease (Crohn’s disease or ulcerative colitis) and around 70,000 new cases of IBD are diagnosed every year in the USA. Hence, the rising prevalence of Crohn's disease and ulcerative colitis is expected to drive the inflammatory bowel disease treatment market. Technological advancement is a key trend gaining popularity in the inflammatory bowel disease treatment market. The key players in the inflammatory bowel disease treatment market are focusing on using technology such as artificial intelligence (AI) for the drug discovery process as well as offering advanced but new inflammatory bowel disease treatments. To attain their technological innovations, key players and technology companies are partnering to leverage each other's competencies and technology to develop new treatments and strengthen their key position in the market. For instance, in May 2021, CytoReason, an Israeli technology start-up developing a computational model of the human body, partnered with Ferring Pharmaceuticals, a Switzerland-based multinational pharmaceutical company to develop new inflammatory bowel disease treatments (IBD) using artificial intelligence technology during the drug discovery process. Ferring's medical expertise will be combined with CytoReason's artificial intelligence (AI) technology to create cell-centred illness models. The AI technology enables scientists to gain critical information on the body’s functioning and treats diseases at the cellular level. In March 2022, Pfizer, Inc., a US-based pharmaceutical and biotechnology company, acquired Arena Pharmaceuticals, Inc., for an amount of $6.7 billion. Through this acquisition, Pfizer will increase its Inflammation and Immunology therapeutic area research capabilities, develop therapies for treatment of immuno-inflammatory diseases, and continue the clinical development of current drug candidates. Arena Pharmaceuticals, Inc., is a US-based biopharmaceutical company specializing in the development of novel prospective treatments for the treatment of various immuno-inflammatory illnesses. Major players in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen, Johnson & Johnson, Amgen Inc., UCB SA, Novartis AG, Takeda Pharmaceutical Company Limited, Merck & Co, Pfizer Inc., Abbott Laboratories, Janssen Biotech Inc., Eli Lilly, Allergan plc, Alkem Laboratories Limited, and Bausch Health Companies Inc., North America was the largest region in the inflammatory bowel disease treatment market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the inflammatory bowel disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The inflammatory bowel disease treatment market includes revenues earned by entities by reducing the inflammation that triggers the signs and symptoms. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced.It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global inflammatory bowel disease treatment market is segmented - 1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes 2) By Type: Crohn's Disease, Ulcerative Colitis 3) By Route of Administration: Oral, Injectable 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Assisted reproductive technology is based on the surgical removal of eggs from women’s ovaries and then fusing them with men’s sperm in the laboratory to create embryos. These embryos are then inserted back into the woman’s body. ART uses donor eggs, donor sperm, or previously stored frozen embryos. Assisted reproductive technology (ART) is used for the treatment of infertility in either eggs or embryos. The main types of assisted reproductive technology are in-vitro fertilization (IVF), artificial insemination (AI-IUI), frozen embryo replacement (FER), and others. In-vitro fertilisation (IVF) is a complicated operation that involves collecting eggs and fertilising them with sperm in a lab to create embryos. These embryos are subsequently implanted into women's reproductive organs. The different procedure types include fresh non-donor, fresh donor, frozen donor, frozen non donor, embryo or egg banking and is used in hospitals, fertility clinics, others. The assisted reproductive technology (ART) market research report is one of a series of new reports from The Business Research Company that provides assisted reproductive technology (ART) market statistics, including assisted reproductive technology (ART) industry global market size, regional shares, competitors with a assisted reproductive technology (ART) market share, detailed assisted reproductive technology (ART) market segments, market trends and opportunities, and any further data you may need to thrive in the assisted reproductive technology (ART) industry. This assisted reproductive technology (ART) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global assisted reproductive technology market size grew from $31.4 billion in 2022 to $37.56 billion in 2023 at a compound annual growth rate (CAGR) of 19.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The assisted reproductive technology market size is expected to grow to $75.64 billion in 2027 at a CAGR of 19.1%. The rising number of infertility cases is expected to foster the assisted reproductive technology market in the coming years. Infertility is defined as the failure to become pregnant after a year of frequent and unprotected intercourse. Infertility affects both men and women, and is typically diagnosed by the inability to conceive. Infertility is treated using assisted reproductive technology (ART). Fertility therapies that work with both a woman's egg and a man's sperm are included in this. For instance, according to the UCLA Health, a US based health system, in 2020 around 15% of couples in the world have trouble in conceiving. Infertile couples are increasingly turning to assisted reproductive technology (ART), which is growing at a rate of 5% to 10% every year. Therefore, the rising number of infertility cases drives the growth of the assisted reproductive technology market. Technological advancements is a key trend gaining the popularity in the assisted reproductive technology market. Major companies operating in the assisted reproductive technology are focused on developing technological solutions to strengthen their position. For instance, in November 2020, NIPD Genetics, a Cyprus based biotechnology company launched Amfira PGT based on Target Capture Enrichment Technology. Amfira PGT is a preimplantation genetic test which can be employed during fertility treatment to improve the odds of becoming pregnant and giving birth to a healthy child. Amfira PGT can be used in In Vitro Fertilization (IVF) cycles to determine whether embryos are chromosomally normal (euploid) and have the best chance of culminating in a safe pregnancy and birth. In August 2021, Virtus Health Limited, an Australia-based company offering assisted reproductive technology acquired Adora Fertility and three-day hospitals from Healius Limited for $45.0 million. This acquisition will help Virtus health to strengthen its portfolio for in-vitro fertilization (IVF). Adora Fertility is an Australia-based company that provide assisted reproductive technology (ART) including IVF (In-vitro fertilisation) and ICSI (Intracytoplasmic Sperm Injection). Major players in the assisted reproductive technology market are Cooper Surgical Inc., Ferring B.V., Hamilton Thorne Ltd., Merck KGaA, Genea Limited, California Cryobank, European Sperm Bank, OvaScience Inc., Bloom IVF Centre, Vitrolife, FUJIFILM Irvine Scientific Inc., Nidacon International AB, Monash IVF Group Ltd., Cook Medical, INVO Bioscience Inc., Thermo Fisher Scientific, Boston Science Corporation, Anecova, Carolinas Fertility Institute, Microm Ltd. Europe was the largest region in the assisted reproductive technology market in 2022. North America was the second-largest region in assisted reproductive technology market. The regions covered in the assisted reproductive technology (ART) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the assisted reproductive technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The assisted reproductive technology market includes revenues earned by entities by gamete intrafallopian transfer (GIFT), zygote intrafallopian transfer (ZIFT), and frozen embryo transfer (FET). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global assisted reproductive technology market is segmented - 1) By Diagnosis: Ovulation Testing, Hysterosalpingography, Ovarian Reserve Testing, Genetic Testing 2) By Procedure Type: Fresh Non-Donor, Fresh Donor, Frozen Donor, Frozen Non-Donor, Embryo Or Egg Banking 3) By End-User: Hospitals, Fertility Clinics, Other End-Users

The hematology drugs market consists of sales of hematology drugs and related services by entities (organizations, sole traders and partnerships) that produce hematology drugs to treat diseases such as genetic disorders, anemia, and other related diseases. This industry includes establishments that produce blood products such as red blood cells, white blood cells, platelets, and fresh frozen plasma. It also consists of establishments which produce of anemia and other blood disorder drugs to treat anemia, hemophilia and blood clots. The main types of hermatology drugs are blood products, anemia and other blood disorder drugs. Any therapeutic substance derived from human blood is referred to as a blood product, which includes whole blood and other blood components for transfusion as well as plasma-derived medicinal products. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global hematology drugs market size is expected to grow from $33.06 billion in 2021 to $36.13 billion in 2022 at a compound annual growth rate (CAGR) of 9.3%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The hematology drugs market is expected to reach $73.67 billion in 2026 at a CAGR of 19.5%. The hematology drugs market growth is aided by stable economic growth forecasted in many developed and developing countries. The International Monetary Fund (IMF) stated that the global GDP growth rate was 3.3% in 2020 and 3.4% in 2021. Recovering commodity prices, after a significant decline in the historic period is further expected to aid the market growth. Developed economies are also expected to register stable growth during the forecast period. Additionally, emerging markets are expected to continue to grow slightly faster than the developed markets in the forecast period. This is expected to increase spending on healthcare services, thereby driving the demand for hematology drugs. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the hematology drugs industry in the historic period. Tranexamic acid is increasingly being used to prevent postpartum hemorrhage (blood loss of over 500 ml or 1,000 ml within 24 hours of childbirth) due to its low price and wide availability. Tranexamic acid is an antifibrinolytic drug that helps in reducing bleeding in surgical and trauma patients, including women with postpartum hemorrhage. According to the World Maternal Antifibrinolytic (WOMAN) trial, using tranexamic acid within three hours of childbirth lowered death from bleeding by 31% and reduced the need for laparotomy (emergency bleeding control surgery) by 36%. The trial included over 20,000 women from 193 hospitals in 21 countries. Major companies in the hematology market include Amgen, Alexion Pharmaceuticals, Bayer AG, F. Hoffmann-La Roche Ltd., CSL, Takeda Pharmaceuticals, Novo Nordisk, Sanofi S.A, Daiichi Sankyo Company and Pfizer Inc. North America was the largest region in the hematology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the hematology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hematology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global hematology drugs market is segmented - 1) By Type: Blood Products, Anemia and Other Blood Disorder Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs